TY - JOUR
T1 - A Case of Metastatic Colon Cancer Dramatically Affected by Anti-EGFR Antibody Therapy
AU - Yagi, Ryoma
AU - Shimada, Yoshifumi
AU - Miura, Kohei
AU - Tajima, Yosuke
AU - Okamura, Takuma
AU - Nakano, Masato
AU - Ichikawa, Hiroshi
AU - Nagahashi, Masayuki
AU - Sakata, Jun
AU - Kobayashi, Takashi
AU - Kameyama, Hitoshi
AU - Wakai, Toshifumi
AU - Nogami, Hitoshi
AU - Maruyama, Satoshi
AU - Takii, Yasumasa
PY - 2016/11/1
Y1 - 2016/11/1
N2 - RAS mutation is an established predictive biomarker of resistance to anti-epidermal growth factor receptor(EGFR)therapy in metastatic colorectal cancer. In addition, previous studies identified mutations in ERBB2, FGFR1, PDGFRA, BRAF, MAP2K1, PTEN, and PIK3CA as potential mechanisms of resistance to anti-EGFR therapy. Testing for these mutations might be necessary to determine eligibility for anti-EGFR therapy in patients with metastatic colorectal cancer. CancerPlex®is a nextgeneration sequencer for 413 cancer genes. An analysis panel includes genes that may be associated with resistance to anti- EGFR therapy. A 65-year-old man with unresectable rectal cancer, multiple lung metastases, and a bulky liver metastasis was evaluated for expression of genes associated with resistance to anti-EGFR. The analysis found that all genes indicating resistance were wild-type genes. Cetuximab monotherapy was administered after rectal resection, with dramatic shrinkage of the metastatic tumors. A more accurate selection of patients according to tumor genetic status using CancerPlex®might improve the risk-benefit profile of anti-EGFR therapy.
AB - RAS mutation is an established predictive biomarker of resistance to anti-epidermal growth factor receptor(EGFR)therapy in metastatic colorectal cancer. In addition, previous studies identified mutations in ERBB2, FGFR1, PDGFRA, BRAF, MAP2K1, PTEN, and PIK3CA as potential mechanisms of resistance to anti-EGFR therapy. Testing for these mutations might be necessary to determine eligibility for anti-EGFR therapy in patients with metastatic colorectal cancer. CancerPlex®is a nextgeneration sequencer for 413 cancer genes. An analysis panel includes genes that may be associated with resistance to anti- EGFR therapy. A 65-year-old man with unresectable rectal cancer, multiple lung metastases, and a bulky liver metastasis was evaluated for expression of genes associated with resistance to anti-EGFR. The analysis found that all genes indicating resistance were wild-type genes. Cetuximab monotherapy was administered after rectal resection, with dramatic shrinkage of the metastatic tumors. A more accurate selection of patients according to tumor genetic status using CancerPlex®might improve the risk-benefit profile of anti-EGFR therapy.
UR - http://www.scopus.com/inward/record.url?scp=85029564743&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029564743&partnerID=8YFLogxK
M3 - Article
C2 - 28133136
AN - SCOPUS:85029564743
SN - 0385-0684
VL - 43
SP - 1800
EP - 1802
JO - Gan to kagaku ryoho. Cancer & chemotherapy
JF - Gan to kagaku ryoho. Cancer & chemotherapy
IS - 12
ER -
